Evidence map›Paper›PMID 41503468›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Integrated Biofluid Proteomics Identified Dynamic Functional Biomarkers of

Cong Xiao, Takahiro Shimizu, Bik Tzu Huang, Duc Tung Vu, Ericka Itang, Matthias Mann, Ozge Karayel, Zhenyu Yue

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cong XiaoCenter for Parkinson's Disease Neurobiology, Department of Neurology, Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Takahiro ShimizuCenter for Parkinson's Disease Neurobiology, Department of Neurology, Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bik Tzu HuangCenter for Parkinson's Disease Neurobiology, Department of Neurology, Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Duc Tung VuProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0002-7573-1591
Ericka ItangProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Matthias MannProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Ozge KarayelProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Zhenyu YueCenter for Parkinson's Disease Neurobiology, Department of Neurology, Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

Neuronal Autophagy: a Cell-Autonomous Protection MechanismR01NS060123 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zhenyu Yue · 2008 to 2026
$9.2M
Determining Selective Autophagy Kinase in Modulating Neurotoxicity in Huntington's Disease ModelR01NS117590 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI YUE, ZHENYU · 2020 to 2024
$2.3M
Determining neuroprotective autophagy functions using different types of human neuronsR21AG067570 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI YANG, NAN, YUE, ZHENYU · 2020 to 2020
$466k
NIA NIH HHS R21 AG067570NINDS NIH HHS R01 NS060123NINDS NIH HHS R01 NS117590
6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) variants are the most common cause of inherited Parkinson's disease (PD), and the hyperactivity of the LRRK2 variants represent a validated drug target for PD. The penetration of common LRRK2 variants is incomplete, underscoring the need for molecular biomarkers that predict disease onset and guide therapeutics development. Here, we analyzed large datasets of cerebrospinal fluid (CSF) and urinary proteomics from the Parkinson's Progression Markers Initiative (PPMI) and identified distinct lysosomal and immune protein signatures as potential biomarkers for LRRK2-linked PD (LRRK2 PD). Longitudinal analysis revealed that levels of specific lysosomal and immune proteins remained elevated in CSF during the prodromal phase but declined following clinical symptom onset. Furthermore, examination of multiple brain cell types from

Identifiers

PMID41503468
PMCPMC12772675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.